Novartis files COPD combo drug in EU
This article was originally published in Scrip
Executive Summary
Novartis has filed for European approval of the chronic obstructive pulmonary disease (COPD) drug, QVA149 (indacaterol maleate/glycopyrronium bromide), a move that triggered milestone payments of $5 million each to partners Vectura and Sosei.